Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Pool Corp amends receivables securitization facility, lifts March-September limit to $400 million

Pool Corp amends receivables securitization facility, lifts March-September limit to $400 million

ReutersReuters2026/08/28 20:07
  • Pool subsidiaries amended a receivables securitization facility on Aug. 25, 2026, extending the termination date to Aug. 25, 2028.
  • Maximum facility limit rises to $400 million in March-September; $300 million in the remaining months.
  • March-September capacity includes $300 million committed, $100 million uncommitted; other months include $200 million committed, $100 million uncommitted.
  • Borrowings price at one-month Term SOFR plus 0.75% for committed tranches; 0.85% for uncommitted tranches.
  • Wells Fargo serves as administrative agent under the amended receivables purchase agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pool Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-374331), on August 28, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Moderna melanoma vaccine data gains recognition; fifth institution upgrades rating

Moderna has recently received consecutive rating upgrades from five institutions due to positive clinical data from its melanoma mRNA cancer vaccine. Argus analyst Hellweg upgraded the company's rating from "hold" to "buy," noting that the stock price is currently trading at over a 70% discount from its historical peak and believing that "the tide is turning." He emphasized that the stock price increase driven by existing data is just the beginning, and that continued positive confirmatory data will provide stronger upward momentum.

华尔街见闻2026/08/28 21:28